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Statins may have nephroprotective as well as cardioprotective effects in patients with car-on of
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tivecomdiovascular disease. In the Treating to New Targets (TNT) study (NCT00327691), patients
with coronary heart disease (CHD) were randomized to atorvastatin 10 or 80 mg/day and
followed for 4.9 years. The relation between intrastudy change in estimated glomerular
ﬁltration rate (eGFR) from baseline and the risk of major cardiovascular events (MCVEs,
deﬁned as CHD death, nonfatal noneprocedure-related myocardial infarction, resuscitated
cardiac arrest, or fatal or nonfatal stroke) was assessed among 9,500 patients stratiﬁed
by renal function: improving (change in eGFR more thanD2 ml/min/1.73 m2), stable (L2
toD2 ml/min/1.73 m2), and worsening (less thanL2 ml/min/1.73 m2). Compared with pa-
tients with worsening renal function (1,479 patients, 15.6%), the rate of MCVEs was 28%
lower in patients with stable renal function (2,241 patients, 23.6%) (hazard ratio [HR] 0.72;
95% conﬁdence interval [CI] 0.60 to 0.87; p [ 0.0005) and 64% lower in patients with
improving renal function (5,780 patients, 60.8%;HR0.36; 95%CI 0.30 to 0.43; p<0.0001). For
each 1 ml/min/1.73 m2 increase in eGFR, the absolute reduction in the rate of MCVEs was
2.7% (HR 0.973; 95% CI 0.967 to 0.980; p <0.0001). An absolute MCVE rate reduction per 1
ml/min/1.73m2 increase in eGFRof 2.0%was reportedwith atorvastatin 10mg and 3.3%with
atorvastatin 80 mg. In conclusion, intrastudy stabilization or increase in eGFR in
atorvastatin-treated patients with CHD from the TNT study was associated with a reduced
rate of MCVEs. Statin-treated CHD patients with progressive renal impairment are at high
risk for future cardiovascular events.  2016TheAuthors. Published byElsevier Inc. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/). (Am J Cardiol 2016;117:1199e1205)Cardiovascular disease (CVD) is associated with a pro-
gressive decrease in renal function and development of
chronic kidney disease (CKD).1 Additionally, rapid declines
in renal function correlate with increased cardiovascular (CV)
mortality, independent of baseline estimated glomerular
ﬁltration rate (eGFR).2,3 Therefore, change in eGFRover timeCardiovascular and Medical Sciences, University of
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mons.org/licenses/by-nc-nd/4.0/).may be a more potent predictor of CV outcomes than baseline
renal function in patientswith CVD.4Clinical trials in patients
with CVD or its risk factors have suggested that statins may
stabilize or improve renal function.5e9 However, the relation
between statin-associated stabilization or improvement of
renal function and CV outcomes has not been analyzed. In
post hoc analyses of the Treating toNewTargets (TNT) study,
we noted dose-dependent improvements in renal function5
and signiﬁcant reductions in CV events10 in atorvastatin-
treated patients with coronary heart disease (CHD) with or
without CKD.Here, we examined the effect of atorvastatin on
renal function over time to assess the relation between
directional change in eGFR and new CV events.Methods
The TNT study was a prospective, double-blind, parallel-
group study conducted from April 1998 to August 2004.11,12
Eligible patients were men and women aged 35 to 75 years
with clinically evident CHD, deﬁned as previous myocardial
infarction (MI), angina with objective evidence of athero-
sclerotic CHD, or previous coronary revascularization pro-
cedure. Patients with nephrotic syndrome were excluded. No
protocol-speciﬁc exclusionswere based on kidney function or
baseline creatinine concentration, although such exclusionswww.ajconline.org
18 469 patients screened
3005 excluded
5461 excluded
4634 did not meet randomization criteria
195 had ischemic events
197 had adverse events
70 did not comply with treatment
16 died
349 for other reasons
15 464 entered open-label 
run-in period
345 with missing creatinine data
10 003 underwent randomization 
(2 not given drug)
9656 with complete renal data 
(both baseline and follow-up 
assessments of eGFR)
156 without post-baseline eGFR 
measurement prior to major 
cardiovascular event
9500 included in eGFR analysis of 
primary endpoint
2241 with stable renal function
(ΔeGFR: −2 to +2 mL/min/1.73 m2)
5780 with improving renal function
(ΔeGFR: >+2 mL/min/1.73 m2)
1479 with worsening renal function
(ΔeGFR:<−2 mL/min/1.73 m2)
Figure 1. Flow chart of TNT participants included in this analysis.
1200 The American Journal of Cardiology (www.ajconline.org)could occur at the investigator’s discretion. After an 8-week
open-label treatment period with atorvastatin 10 mg/day
(baseline), patients with a mean low-density lipoprotein
cholesterol (LDL-C) 3.4 mmol/L (130 mg/dl) were ran-
domized to atorvastatin 10 or 80 mg/day (Figure 1).
Only those patients with both a baseline and at least 1
post-baseline serum creatinine measurement were included
in this post hoc analysis. Serum creatinine levels were
measured at baseline and after 12, 24, 36, 48, 60, and
72 months of treatment using the modiﬁed alkaline picrate
method of Jaffé.13,14 Samples were analyzed by a central
study laboratory blinded to treatment assignment. Standards
by the College of American Pathologists were used for in-
ternal quality assurance and external calibration and vali-
dation to ensure accuracy and reproducibility of the
creatinine measurement throughout the study. To provide
consistency with previous renal analyses of the TNT
data,5,10 eGFR was determined using the 4-component
Modiﬁcation of Diet in Renal Disease (MDRD) equation15
and staged according to Kidney Disease Outcomes Quality
Initiative guidelines.16
We used a last observation carried forward (LOCF)
analysis to determine the ﬁnal eGFR measurement. On-
treatment change in eGFR was stratiﬁed into 1 of 3 cate-
gories based on predeﬁned clinical classiﬁcations of change
in renal function over time: improving (change in eGFR
more than þ2 ml/min/1.73 m2), stable (2 to þ2 ml/min/
1.73 m2), or worsening (less than 2 ml/min/1.73 m2). The
primary efﬁcacy outcome was time to occurrence of a majorcardiovascular event (MCVE; CHD death, nonfatal
noneprocedure-related MI, resuscitated cardiac arrest, or
fatal or nonfatal stroke). The relation between change in
eGFR and MCVEs was assessed by a multivariable and
time-dependent Cox proportional hazards model, which
included change from baseline to the end of study or last
available eGFR (continuous scale) as the time-dependent
independent variable adjusting for baseline factors
including eGFR, age, gender, smoking status, body mass
index (BMI), LDL-C, and history of hypertension (or anti-
hypertensive use), diabetes (or antidiabetic medication use),
coronary artery bypass graft (CABG) surgery, percutaneous
coronary intervention, angina, cerebrovascular disease, pe-
ripheral vascular disease (PVD), congestive heart failure,
and arrhythmia. We also carried out 2 additional Cox pro-
portional hazards analyses: a multivariable model that
included change in eGFR from baseline to year 1 and a
time-dependent model that included all changes in eGFR
from baseline to the ﬁrst event or end of study as the time-
dependent independent variable. Both models adjusted for
baseline eGFR, change in LDL-C, and treatment. Compar-
isons of baseline characteristics were based on 1-way
analysis of variance with pairwise comparison for contin-
uous variables, and Fisher’s exact test for overall test and
logistic regression analysis with pairwise comparisons for
categorical variables. Changes in eGFR from baseline to
ﬁnal measurement were compared by an analysis of
covariance model adjusting for baseline eGFR. A
similar model compared change from baseline to month 3
Figure 2. Frequency distribution of eGFR in the TNT renal cohort
(n ¼ 9,656) at baseline (top) and at last visit before primary end point
(bottom).
Coronary Artery Disease/TNT eGFR and CV Outcomes 1201in LDL-C, high-density lipoprotein cholesterol (HDL-C),
and triglycerides. Hazard ratios (HRs) and 95% conﬁdence
intervals (CIs) were calculated using a Cox proportional
hazards model. Two-sided log-rank p values <0.05 were
regarded as signiﬁcant. All analyses were performed using
SAS (version 9.12 or later).Results
In TNT, 10,001 patients were randomly assigned to
double-blind treatment with either atorvastatin 10 or 80 mg/
day with a median follow-up of 4.9 years.11,12 Of the 9,656
patients with both baseline and post-baseline eGFR mea-
surements, 67.8% (n ¼ 6,549) had an eGFR 60 ml/min/
1.73 m2, whereas 32.2% (n ¼ 3,107) had an eGFR <60 ml/
min/1.73 m2 (predominantly CKD stage 3); the baseline
characteristics of this TNT renal cohort have been previ-
ously reported.5,10 A total of 156 patients experienced an
MCVE before the ﬁrst post-baseline eGFR assessment and
were excluded, leaving 9,500 patients eligible for this
analysis (Figure 1).In this TNT renal subgroup, 417 patients (8.8%) receiving
atorvastatin 10 mg and 340 patients (7.1%) receiving ator-
vastatin 80 mg experienced an MCVE, corresponding to a
19% reduction in MCVE risk in patients receiving atorvas-
tatin 80 versus 10 mg (HR 0.81; 95% CI 0.70 to 0.93;
p ¼ 0.0030). Mean (SD) eGFR at baseline was 65.6 
11.4ml/min/1.73m2 in the atorvastatin 10-mg group and 65.0
 11.2 ml/min/1.73 m2 in the atorvastatin 80-mg group. As
seen in the total TNT renal cohort,5 mean eGFR increased
progressively from baseline in both treatment groups. Over-
all, mean eGFR rose from 65.3  11.3 ml/min/1.73 m2 at
baseline to 69.7  14.6 ml/min/1.73 m2 at study end, an
increase of 4.4  9.8 ml/min/1.73 m2 (þ6.7%) and a shift
toward higher eGFR values with a broader distribution, as
shown for the total renal cohort (Figure 2). Mean eGFR
increased by 3.6  9.8 ml/min/1.73 m2 (þ5.5%) in the ator-
vastatin 10-mg arm and 5.2 9.8ml/min/1.73m2 (þ8.0%) in
the atorvastatin 80-mg arm. The difference in least-squares
mean change in eGFR from baseline between the treatment
groups of 1.6 ml/min/1.73 m2 was signiﬁcant (95%CI 1.20 to
1.99; p <0.0001). In the total TNT renal cohort (n ¼ 9,656),
this increase in eGFR was observed in both treatment groups
regardless of baseline CKD status.5
In the present analysis (n ¼ 9,500), change from baseline
eGFR was signiﬁcantly associated with MCVEs, major
coronary events, all-cause, and CV mortality. Overall, a
1 ml/min/1.73 m2 increase in eGFR was associated with a
2.7% absolute reduction in the rate of MCVEs (HR 0.973;
95% CI 0.967 to 0.980; p <0.0001). Results from the 1-year
eGFR change sensitivity analysis had a lower level of pre-
dictability and a marginally insigniﬁcant effect (HR per 1
ml/min/1.73 m2 increase, 0.990; 95% CI 0.979 to 1.002;
p ¼ 0.090). Using the time-dependent model, changes in
renal function signiﬁcantly predicted MCVEs (HR per 1 ml/
min/1.73 m2 increase, 0.965; 95% CI 0.959 to 0.972;
p <0.001) to a similar extent as the original model.
Change in eGFR was associated with CV end points for
both atorvastatin 10- and 80-mg treatments, but the reduc-
tion in the rate of events associated with increasing eGFR
was signiﬁcantly greater in patients receiving atorvastatin
80 mg (absolute event rate reduction per 1 ml/min/1.73 m2
increase in eGFR: 2.0% with atorvastatin 10 mg; 3.3% with
atorvastatin 80 mg; interaction p ¼ 0.0107). This corre-
sponds to a 7.1% absolute reduction in MCVE rate for the
observed increase of 3.6 ml/min/1.73 m2 in eGFR with
atorvastatin 10 mg and a 16.2% reduction in MCVE rate for
the 5.2 ml/min/1.73 m2 increase in eGFR with atorvastatin
80 mg.
Classiﬁcation of the directional change in eGFR (base-
line to last observation) identiﬁed 1,479 patients (15.6%)
with worsening renal function, 2,241 patients (23.6%) with
stable renal function, and 5,780 patients (60.8%) with
improving renal function over 5 years of follow-up. Sub-
jects with worsening renal function were signiﬁcantly older
and more likely women, and had a higher BMI, greater
likelihood of hypertension or diabetes, and higher preva-
lence of CABG, PVD, and cerebrovascular disease at
baseline than those with stable or improving renal function
(Table 1).
Mean eGFR in patients whose renal function worsened
was signiﬁcantly lower at baseline versus those whose renal
Table 1
Baseline characteristics of patients included in this analysis, stratiﬁed by directional change in estimated glomerular ﬁltration rate
Baseline characteristic
(at randomization)
Change in estimated glomerular ﬁltration rate (ml/min/1.73 m2)
Worsening (<2)
(n¼1479)
Stable (2 to þ2)
(n¼2241)
Improving (>þ2)
(n¼5780)
Men 1113 (75%) 1761 (79%)* 4829 (84%)*
Mean age (years) 63.58.8 61.28.8* 60.38.7*
White 1378 (93%) 2100 (94%) 5471 (95%)*
Current smoker 201 (14%) 322 (14%) 713 (12%)
Systolic blood pressure (mmHg) 135.118.1 131.216.5* 129.316.3*
Diastolic blood pressure (mmHg) 78.19.7 78.09.5 77.99.4
Low-density lipoprotein cholesterol (mmol/l [mg/dl]) 2.520.46 [97.617.6] 2.510.44 [97.017.2] 2.520.46 [97.617.6]
High-density lipoprotein cholesterol (mmol/l [mg/dl]) 1.220.30 [47.211.5] 1.240.28 [47.910.9]* 1.220.28 [47.210.8]
Total cholesterol (mmol/l [mg/dl]) 4.540.64 [175.424.6] 4.500.60 [173.923.1] 4.520.62 [174.723.8]
Triglycerides (mmol/l [mg/dl]) 1.740.83 [154.373.4] 1.650.77 [146.168.4]* 1.700.79 [150.369.6]*
MDRD estimated glomerular ﬁltration rate (ml/min/1.73 m2) 65.013.7 68.311.1* 64.210.5*
Body mass index (kg/m2) 29.15.1 28.44.7* 28.44.3*
Chronic kidney disease† 542 (37%) 529 (24%)* 1978 (34%)
Angina pectoris 1214 (82%) 1805 (81%) 4725 (82%)
Myocardial infarction 864 (58%) 1294 (58%) 3352 (58%)
Coronary angioplasty 762 (52%) 1211 (54%) 3170 (55%)*
Coronary artery bypass graft 779 (53%) 1039 (46%)* 2588 (45%)*
Hypertension 995 (67%) 1220 (54%)* 2918 (50%)*
Diabetes mellitus 388 (26%) 300 (13%)* 706 (12%)*
Peripheral vascular disease 272 (18%) 260 (12%)* 571 (10%)*
Congestive heart failure 215 (15%) 151 (7%)* 349 (6%)*
Cerebrovascular disease 109 (7%) 117 (5%)* 252 (4%)*
Values are number (%) or mean SD.
* p <0.05 versus patients with worsening renal function.
† eGFR <60 ml/min/1.73 m2.
1202 The American Journal of Cardiology (www.ajconline.org)function remained stable but signiﬁcantly higher than those
with improving renal function (Table 2). A higher proportion
of patients with improving renal function, and a lower pro-
portion of those with worsening or stable renal function, were
assigned to atorvastatin 80 mg, and this trend was signiﬁcant
across renal subgroups (Table 2). Compared with the sub-
group with worsening renal function, the relative risk of
MCVEs was 28% lower in patients with stable renal function
and 64% lower in patients with improving renal function
(Table 2; Figure 3). We conﬁrmed these results using a pre-
dictive analysis using year 1 change in eGFR (Figure 4).
Reductions from baseline to month 3 in LDL-C and tri-
glyceride levels in patients with improving renal function
were signiﬁcantly greater versus those with worsening renal
function (Table 2). Decreases in LDL-C and triglycerides at
3 months were also greater in patients with stable renal
function compared with worsening renal function but not
signiﬁcantly so. Change in HDL-C showed no signiﬁcant
differences across renal subgroups (Table 2).
Discussion
In the TNT trial, CV event reductions after atorvastatin
therapy were achieved both in patients with and without
CKD at baseline.10 This current analysis has revealed that
change in eGFR over the course of the trial was predictive of
MCVEs when using an LOCF analysis. Although the as-
sociation with MCVE risk was diluted in the 1-year eGFR
sensitivity analysis, the time-dependent model captured thepredictive value of change in eGFR in a similar manner to
the LOCF model. MCVE risk was strongly related to the
directional change in eGFR. Compared with those with
worsening renal function, patients with improving renal
function experienced a 64% reduction in relative MCVE
risk, whereas those with stable renal function experienced a
28% reduction; these results were conﬁrmed in an analysis
based on year 1 change in eGFR.
The observation that CV risk may change concurrently
with renal function is not new.2,3,17 Until now, however, few
studies have commented on the relation between improving
renal function and CV events.17 To our knowledge, this
analysis is one of the ﬁrst to suggest that stabilization (and
improvement) of renal function with statin therapy is
strongly associated with a reduction in CV events in patients
with CHD. These observations are supported by a sub-
analysis of the Greek Atorvastatin and Coronary Heart
Disease Evaluation (GREACE) trial, in which patients with
CHD receiving atorvastatin had a 12% increase in creatinine
clearance versus a 5.2% decrease in those receiving usual
care.6 A multivariate model predicted that each 5% increase
in creatinine clearance was associated with a 16% reduction
in CHD-associated events.6
On the basis of this and other TNT subanalyses, the effect
of atorvastatin on renal function and subsequent MCVE risk
appears to be drug related, dose dependent, and occurs over a
wide range of baseline renal function. Patients with improved
renal function were signiﬁcantly more likely to receive ator-
vastatin 80 mg, whereas those with worsening renal function
Figure 3. Kaplan-Meier curves for time to primary end point in deﬁned
renal subgroups using an LOCF analysis. Renal function was deﬁned as
improving (change in eGFR more than þ2 ml/min/1.73 m2), stable (2
to þ2 ml/min/1.73 m2), or worsening (less than 2 ml/min/1.73 m2).
K-M ¼ Kaplan-Meier.
Table 2
Clinical outcomes in the renal function subgroups
Change in estimated glomerular ﬁltration rate (ml/min/1.73 m2)
Worsening (<2)
(n¼1479)
Stable (2 to þ2)*
(n¼2241)
Improving (>þ2)*
(n¼5780)
Number (%) of patients with
primary end point
208 (14.1%) 235 (10.5%) 314 (5.4%)
Hazard ratio (95% conﬁdence
interval) for primary end point
1.00 0.72 (0.60, 0.87) p¼0.0005 0.36 (0.30, 0.43) p<0.0001
Serum creatinine (mmol/l [mg/dl])
Baseline 104.322.1 [1.180.25] 99.915.9 [1.130.18] p<0.0001 107.016.8 [1.210.19] p<0.0001
Change from baseline† 20.331.8 [0.230.36] e0.184.24 [e0.0020.048] p<0.0001 e14.18.0 [e0.160.09] p<0.0001
Estimated glomerular ﬁltration rate (ml/min/1.73 m2)
Baseline 65.013.7 68.311.1 p<0.0001 64.210.5 p¼0.0203
Change from baselinez e10.96.9 e0.980.41 p<0.0001 10.35.9 p<0.0001
Lipids: Change from baseline (mmol/l [mg/dl])x
Low-density lipoprotein
cholesterol
e0.250.55 [e9.721.3] e0.260.53 [e10.120.5] p¼0.2892 e0.340.55 [e13.121.3] p<0.0001
High-density lipoprotein
cholesterol
e0.0010.147 [e0.045.68] 0.0050.142 [0.195.49] p¼0.0906 e0.0040.139 [e0.155.38] p¼0.5485
Triglycerides e0.080.57 [e7.150.4] e0.090.60 [e8.053.1] p¼0.0728 e0.140.59 [e12.452.2] p<0.0001
Atorvastatin 10 mg 833 (56.3%) 1185 (52.9%) 2719 (47.0%)
Atorvastatin 80 mg 646 (43.7%) 1056 (47.1%) 3061 (53.0%)
Overall p-value (trend){ p<0.0001
Values are number (%) or mean SD unless otherwise stated.
* p-values versus patients with worsening renal function.
† Change from baseline to ﬁnal visit.
z Change from baseline to the last measurement prior to primary end point.
x Change from baseline to month 3.
{ p-value based on Cochran-Armitage test for trend.
Coronary Artery Disease/TNT eGFR and CV Outcomes 1203more likely received atorvastatin 10 mg. Differences in
atorvastatin dose, exposure, and resulting LDL-C and tri-
glyceride reductions may have partly contributed to differ-
ences in CV event reduction between those with improving
versus worsening renal function. Mean LDL-C reductions
differed between the group with declining versus stable or
improving renal function; however, these differences were
numerically small (<0.1 mmol/l [4 mg/dl]). Moreover, sta-
tistically signiﬁcant differences in on-treatment lipid levels
were not observed between those with worsening renal
function and stable renal function. Therefore, it is unlikely
that lipid lowering alone accounted for the differences in CV
event reduction observed across the 3 renal function
subgroups.
Annual decreases in eGFRhave been observed in high-risk
patients with CVD, CHD, and dyslipidemia.18,19 In the TNT
renal cohort, a shift toward a higher eGFR with atorvastatin
therapy was detected. Moreover, stabilization or improve-
ment of renal function occurred in w84% of TNT patients
included in this current analysis. This observation is notable
and may be clinically relevant: CVD has been independently
associated with a more rapid decrease in renal function,1 and
atherosclerosis may foreshadow underlying renal microvas-
cular disease.20 Indeed, TNT patients with worsening renal
function had signiﬁcantly higher prevalence of CV risk fac-
tors and target organ damage at baseline, including PVD,
heart failure, and stroke.
Tonelli et al18 ﬁrst noted a beneﬁcial effect of statins
on renal function in CHD patients with an eGFR<40ml/min/1.73 m2, in whom progression of renal disease was slowed
signiﬁcantly with pravastatin versus placebo. For atorvasta-
tin, beneﬁcial effects on renal function have been observed in
a number of trials across a wide range of patient populations,
including those with CHD, diabetes, and CKD.5,6,21,22 The
mechanism behind atorvastatin’s effect on renal function is
unclear. LDL-C has been linked to mesangial cell prolifera-
tion in the kidney23 and increased production of inﬂammatory
Figure 4. Kaplan-Meier curves for time to primary end point in deﬁned
renal subgroups using a predictive model incorporating change in eGFR
over 1 year. Renal function was deﬁned as improving (change in eGFR
more than þ2 ml/min/1.73 m2), stable (2 to þ2 ml/min/1.73 m2), or
worsening (less than 2 ml/min/1.73 m2). K-M ¼ Kaplan-Meier.
1204 The American Journal of Cardiology (www.ajconline.org)markers. In addition to lipid effects, atorvastatin has demon-
strated reductions in markers of inﬂammation and oxidative
stress.24,25 Thus, potent statins with anti-inﬂammatory prop-
erties may act to slow kidney disease progression in addition
to reducing CV risk. However, the Study of Heart and Renal
Protection (SHARP) trial found no effect of simvastatin plus
ezetimibe versus placebo on progression of kidney disease in
a large cohort of nondialysis patients with moderate CKD.26
Also, a recent analysis of the Prospective Evaluation of Pro-
teinuria and Renal Function in Diabetic/Non-Diabetic Pa-
tients with Progressive Renal Disease (PLANET) I and II
trials demonstrated that rosuvastatin was associated with
signiﬁcantly greater decreases in eGFR versus atorvastatin.27
Moreover, atorvastatin was associated with signiﬁcantly
greater reductions in proteinuria,27 indicating that—together
with the SHARP ﬁndings—renoprotection may not be a class
effect.
We acknowledge several limitations of this analysis in
addition to those previously discussed for TNT.10 To pro-
vide consistency with previous analyses of the TNT renal
population,5,10 we used the modiﬁed MDRD equation,
which is known to underestimate renal function in the
normal range compared with direct measurements of GFR.28
Proteinuria, which may help deﬁne CV risk in conjunction
with eGFR,29 was not systematically assessed in TNT.
Finally, the observed renal beneﬁt may be limited to patients
with CHD and normal renal function or those with milder
degrees of renal impairment (stage 3 CKD).Acknowledgment: Assistance with statistical analyses was
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